Biomimetics for treating biofilm-embedded infections

Award Information
Agency:
Department of Defense
Branch
Army
Amount:
$749,860.00
Award Year:
2010
Program:
STTR
Phase:
Phase II
Contract:
W911NF-10-C-0111
Agency Tracking Number:
A09A-004-0108
Solicitation Year:
n/a
Solicitation Topic Code:
ARMY 09T004
Solicitation Number:
n/a
Small Business Information
PolyMedix, Inc.
170 N. Radnor-Chester Road, Suite 300, Radnor, PA, 19087
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
621470033
Principal Investigator:
Richard Scott
VP Research
(484) 598-2336
rscott@polymedix.com
Business Contact:
Dawn Eringis
Director, Scientific Affairs
(484) 598-2334
deringis@polymedix.com
Research Institution:
University of Massachusetts Amherst
Carol Sprague
Office of Grants and Contract
70 Butterfield Terrace
Amherst, MA, 1003
(413) 545-0698
Nonprofit college or university
Abstract
Multi-drug resistant (MDR) biofilms are one of the most difficult bacterial infections to treat. Current antibiotics are increasingly unable to cure these infections; underscoring the need to develop new antibiotics that operate through novel mechanisms which overcome the biofilm environment. PolyMedix has discovered a novel class of antibiotics, SMAMPS (small mimics of antimicrobial peptides), that work through a mechanism which appears to evade resistance development and is not depended on bacterial growth. One SMAMP is currently in human clinical trials to treat nosocomial infections, including methicillin-resistant S. aureus. During the Phase I STTR, potently active lead compounds were identified against pathogens associated with biofilm-embedded infections. Resistance to other antibiotics did not influence susceptibility to the PMX mimetics. Rapid killing kinetics and a low risk for the development of resistance are hallmark features of PMX mimetics and underscore their potential as novel antimicrobial agents suitable for further development for treatment of infections complicated by biofilm formation. This Phase II STTR aims to identify SMAMPs that are potently active in in vitro and in vivo biofilm infection models and possess pharmaceutical qualities suitable for further development.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government